ClinicalTrials.gg
Status unknownNCT05663411Updated Jun 18, 2023

A Study of SHR6508 in Secondary Hyperparathyroidism

A Phase 2 interventional study of SHR6508 and SHR6508 in Secondary Hyperparathyroidism, sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-18.

Sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Nov 2022), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Hyperparathyroidism, Secondary with a site in China — 4 open to participants now, 5 under way, 1 of them phase 3. Hyperparathyroidism, Secondary · China.

Enrollment
13th of 18
75 · median 158
Started
2023
with 3 others
Phase 2
5 of 23
1 open now
Registered
13th of 23
by date
Lead sponsor
5 of 23
Shanghai Hengrui Pharmaceutical Co., Ltd.

Among the 23 studies in Hyperparathyroidism, Secondary with a site in China, this one is the 13th largest by enrollment of the 18 interventional ones that give a count, is one of 4 that started in 2023, is one of 5 in phase 2, and was the 13th registered.

Hyperparathyroidism, Secondary

188 studies on the registry are indexed under Hyperparathyroidism, Secondary; 15 are open to participants now.

Browse Hyperparathyroidism, Secondary studies →

Open to participants now

4 of the 23 studies in Hyperparathyroidism, Secondary with a site in China are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 10 Hyperparathyroidism, Secondary studies recruiting now, 5 (50%) set no upper age limit and 4 (40%) stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Hyperparathyroidism, Secondary with a site in China, or all of them as a file.
02

Study summary

The study is being conducted to evaluate the efficacy and safety of SHR6508 for Chinese patients with secondary hyperparathyroidism of chronic kidney disease treated by maintenance hemodialysis.

03

Conditions studied

  • Secondary Hyperparathyroidism
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to provide a written
  2. Diagnosed with end stage renal disease receiving stable hemodialysis
  3. Male or female
  4. Meet the standard
  5. Stably use of concomitant medication of other therapies of SHPT
  6. Meet the standard of iPTH level, cCa and HB

Exclusion criteria

Exclusion Criteria:

  1. Subjects with a history of malignant tumor
  2. Subjects with neuropsychiatric diseases
  3. Subjects with a history of cardiovascular diseases
  4. Subjects with gastrointestinal diseases
  5. Subjects with a history of surgery
  6. Subjects with a history of blood loss
  7. Subjects with a history of kidney transplant
  8. Abnormal blood pressure, serum magnesium, serum transaminase, serum albumin
  9. Subjects with a treatment history of similar drugs
  10. Allergic to a drug ingredient or component
  11. Pregnant or nursing women
  12. No during the specified period of time
  13. Subject with a history of alcohol abuse and drug abuse
  14. Participated in clinical trials of other drugs
  15. The investigators determined that other conditions were inappropriate for participation in this clinical trial
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
75 participants (actual)

Study arms

  • Experimental
    Treatment group A: SHR6508

    Drug: SHR6508

  • Experimental
    Treatment group B: SHR6508

    Drug: SHR6508

  • Active comparator
    Treatment group C: Cinacalcet

    Drug: Cinacalcet

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in serum iPTH

    iPTH was tested at a central laboratory.

    Time frame: Baseline and the efficacy period, defined as Week 16

Secondary outcomes

  1. Proportion of Participants to End of Study whose iPTH decreased by≥30% from baseline

    iPTH was tested at a central laboratory.

    Time frame: Baseline and the efficacy period, defined as Week 16

  2. Proportion of Participants to End of Study whose iPTH decreased to 300 pg/mL from baseline

    iPTH was tested at a central laboratory.

    Time frame: Baseline and the efficacy period, defined as Week 16

  3. Change From Baseline in serum cCa and P

    cCa and P were tested at a local laboratory.

    Time frame: Baseline and the efficacy period, defined as Week 16

  4. Participants With Treatment-Emergent Adverse Events (TEAEs)

    Terms were coded with Medical Dictionary for Regulatory Activities (MedDRA)

    Time frame: Day1 to End of Study, End of Study is about Week 20

  5. Participants with Anti-SHR6508 Antibody at baseline and postbaseline

    Time frame: Day1 to End of Study, End of Study is about Week 20

07

Study locations

1 site
  • Guangdong Provincial People's Hospital
    Guangzhou, Guangdong 510000, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2023 (actual). Primary completion is estimated for Oct 2023, 8 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2022
First posted
Dec 23, 2022
StartActual
Feb 24, 2023
Primary completionEst.
Oct 31, 2023
CompletionEst.
Nov 30, 2023
Last update
Jun 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05663411
Responsible party
Sponsor
First posted
Dec 23, 2022
Start date
Feb 24, 2023
Primary completion
Oct 31, 2023 (estimated)
Completion
Nov 30, 2023 (estimated)
Last update
Jun 18, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SHR6508

Start the discussion